Literature DB >> 23105370

Tissue polypeptide specific antigen in the post therapeutic evaluation of patients with ovarian and colorectal cancer.

Sharmila Upadhya1, Subramanya Upadhya, D M Vasudevan.   

Abstract

The study was designed to evaluate the significance of tissue polypeptide specific antigen (TPS) in patients with histologically proven ovarian and colorectal cancer following treatment along with CA125 (in ovarian cancer) and CEA (in colorectal cancer). Patients were grouped as follows:: Patients with stable disease: Patients with metastasis and relapseIn patients with ovarian and colorectal cancer, the mean TPS levels were significantly higher in patients of group II compared to group I. The percentage of patients above cut-off levels for TPS were 17.4% in group I and 95.5% in group II. Similar results were observed with the mean levels of CA125. In colorectal cancer patients, the percentage of patients above cut-off levels for CEA and TPS were 70% and 30% in group I and 100% in group II for both the markers. Our observations indicate that TPS may be used as a common marker to indicate metastases in patients with ovarian and colorectal cancer.

Entities:  

Keywords:  CA125; CEA; Colorectal cancer; Ovarian cancer; TPS

Year:  2003        PMID： 23105370      PMCID： PMC3453738          DOI： 10.1007/BF02867664

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN： 0970-1915


  20 in total

1.  Serum levels of CA 125 and TPS during treatment of ovarian cancer.

Authors:  A Van Dalen; J Favier; L Baumgartner; U Hasholzner; H De Bruijn; D Dobbler; V H Dombi; D Fink; M Giai; P McGing; A Harlozinska; C Kainz; J Markowska; R Molina; C Sturgeon; A Bowman; R Einarsson
Journal:  Anticancer Res       Date:  2000 Nov-Dec       Impact factor: 2.480

2.  CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA).

Authors:  B Hanke; C Riedel; S Lampert; K Happich; P Martus; H Parsch; B Himmler; W Hohenberger; E G Hahn; A Wein
Journal:  Ann Oncol       Date:  2001-02       Impact factor: 32.976

3.  Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.

Authors:  A van Dalen; J Favier; A Burges; U Hasholzner; H W de Bruijn; D Dobler-Girdziunaite; V H Dombi; D Fink; M Giai; P McGing; A Harlozinska; C Kainz; J Markowska; R Molina; C Sturgeon; A Bowman; R Einarsson
Journal:  Gynecol Oncol       Date:  2000-12       Impact factor: 5.482

4.  Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer.

Authors:  A Zygmunt; R Madry; J Markowska; Z Fischer
Journal:  Eur J Gynaecol Oncol       Date:  1999       Impact factor: 0.196

5.  CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.

Authors:  D Griesenberg; R Nürnberg; M Bahlo; R Klapdor
Journal:  Anticancer Res       Date:  1999 Jul-Aug       Impact factor: 2.480

6.  The biochemistry of CYFRA 21-1 and other cytokeratin-tests.

Authors:  H Bodenmüller
Journal:  Scand J Clin Lab Invest Suppl       Date:  1995

7.  New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancer.

Authors:  G J Locker; R M Mader; J Braun; A E Sieder; C Marosi; H Rainer; R Jakesz; G G Steger
Journal:  Oncology       Date:  1995 Mar-Apr       Impact factor: 2.935

8.  Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients.

Authors:  C Tempfer; L Hefler; G Haeusler; A Reinthaller; H Koelbl; H Zeisler; C Kainz
Journal:  Int J Cancer       Date:  1998-06-19       Impact factor: 7.396

9.  Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements.

Authors:  B Glimelius; K Hoffman; R Einarsson; L Pählman; W Graf
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

10.  Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours.

Authors:  G Kornek; T Schenk; M Raderer; M Djavarnmad; W Scheithauer
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.